Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease.
about
Therapy for Parkinson's disease: what is in the pipeline?A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's diseasePrecompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's DiseaseKnowledge management for efficient quantitative analyses during regulatory reviews.Clinical pharmacology = disease progression + drug actionBayesian quantitative disease-drug-trial models for Parkinson's disease to guide early drug development.How to optimize the treatment of early stage Parkinson's disease.Experimental designs for small randomised clinical trials: an algorithm for choice.A review of disease progression models of Parkinson's disease and applications in clinical trialsDose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease.How should we treat a patient with early Parkinson's disease?Creation of a knowledge management system for QT analyses.Parkinson's disease--the continuing search for biomarkers.Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.Prerequisites to launch neuroprotective trials in Parkinson's disease: an industry perspective.The current role of model-based drug development.Obstacles to the development of a neuroprotective therapy for Parkinson's disease.An economic model of Parkinson's disease: implications for slowing progression in the United States.Disease progression and neuroscience.Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency.Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success.Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development.Development of a placebo effect model combined with a dropout model for bipolar disorder.Neuroprotective Surgical Strategies in Parkinson's Disease: Role of Preclinical Data.Interpreting the results of Parkinson's disease clinical trials: time for a change.Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.Disease-modifying effect of etanercept versus sulphasalazine on spinal mobility in patients with ankylosing spondylitis.Clinical studies and anti-inflammatory mechanisms of treatments.Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States.Conditioning Against the Pathology of Parkinson's disease
P2860
Q26991826-25858E4D-4241-4D47-B23F-0A52E33F187FQ28544423-2ACC11EE-1C17-411B-A093-AF001545217FQ28601965-C435174B-8139-4F77-885E-E2A8D17D28A6Q34082039-A71F6C82-123A-4ECD-A07D-AFBE054FE35FQ34953659-DF0AD203-0C84-45FD-BAFC-E463C33B1ADBQ35595794-FAF3B708-CA9A-4245-AAA6-FF675AD6B3BFQ35599297-046B1112-081A-4279-BDDD-B9B919B19B3AQ36793954-B496F84F-9B20-4CC3-A6FC-CCD9BB7E0560Q37062838-EA312FFE-07BA-450E-AFC0-CC382783F140Q37343974-AE86AE22-5EC4-437E-8E89-D5157C1C7CABQ37775098-94C0EBC5-0CD0-4690-9FFE-842E88BAF5C9Q37803310-D16D558E-D9E9-4E1A-B98F-AB915E99B4ACQ37834648-9BE9E653-1623-454F-B370-7C4A1F46A5B7Q37886138-46C0C121-42B3-478A-8075-8CC1C0B7FF0AQ37939755-156DC337-185F-42C8-BFA5-FA874DDF49A2Q38003066-9B3E6A3F-21DA-46BF-B84B-F0198F1F61D7Q38028538-575185B1-2A77-4877-BC84-E7A9B50D0A79Q38079790-C470E6E7-626F-4BAD-850F-A0C2D46853F3Q38081100-BE3AB63D-FE67-4D7E-9511-01EC7BE4F91AQ38099584-5B19C5F6-74F8-4270-A596-175488A1894AQ38832928-2E91AFE8-A924-4115-AB16-695A04766D35Q38853071-BC781E4F-99BC-494B-9F21-DBA2338BBE4AQ39828349-548D5932-A3FA-4E4E-B104-21A8D16E1DC5Q41819996-890EDC91-3617-4016-94C7-F3135B509048Q43480141-F4124E48-EBC7-45C0-AB8E-0C2A53363C95Q44266420-289FF861-D353-4A80-A82B-89F173EBE314Q45797972-C2375029-8BC5-4714-BBF2-6CEDB020E9C1Q45945368-E0FE01CB-97B8-4A34-AEDD-967E23AE69CCQ46050990-E7CBA247-6064-415B-BFA8-34330937541FQ47124754-EEF0832F-353E-4946-8C41-C740425B4A6DQ48017570-0EE1914D-E930-4AC4-AAE6-9DFFB029FB2CQ50073420-B9C9234A-DA16-4605-BA78-3041E9970852Q58131545-2407FC2E-6641-437E-B545-2B540DFEAB47
P2860
Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Endpoints and analyses to disc ...... in early Parkinson's disease.
@en
Endpoints and analyses to disc ...... in early Parkinson's disease.
@nl
type
label
Endpoints and analyses to disc ...... in early Parkinson's disease.
@en
Endpoints and analyses to disc ...... in early Parkinson's disease.
@nl
altLabel
Endpoints and Analyses to Disc ...... s in Early Parkinson’s Disease
@en
prefLabel
Endpoints and analyses to disc ...... in early Parkinson's disease.
@en
Endpoints and analyses to disc ...... in early Parkinson's disease.
@nl
P2093
P2860
P1433
P1476
Endpoints and analyses to disc ...... in early Parkinson's disease.
@en
P2093
Jogarao V S Gobburu
Leonard P Kapcala
Ohidul Siddiqui
Venkatesh Atul Bhattaram
P2860
P2888
P304
P356
10.1208/S12248-009-9123-2
P407
P577
2009-06-12T00:00:00Z
P5875
P6179
1022465899